{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:00:41Z","timestamp":1793336441197,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.bmcl.2018.06.029","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T19:57:21Z","timestamp":1529351841000},"page":"2985-2992","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Squaramides as novel class I and IIB histone deacetylase inhibitors for topical treatment of cutaneous t-cell lymphoma"],"prefix":"10.1016","volume":"28","author":[{"given":"Jean-Fran\u00e7ois","family":"Fournier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushma","family":"Bhurruth-Alcor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branislav","family":"Musicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9rome","family":"Aubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mich\u00e8le","family":"Aurelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Bouix-Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karinne","family":"Bouquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Chantalat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Delorme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Drean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwenaelle","family":"Duvert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Fleury-Bregeot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanche","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Grisendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig S.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent F.","family":"Hennequin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Isabet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Lafitte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Millois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9my","family":"Morgentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Pascau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Piwnica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Rival","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Soulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9tienne","family":"Thoreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc","family":"Tomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2018.06.029_b0005","first-page":"377","article-title":"Update on the treatment of cutaneous T-cell lymphoma (CTCL): focus on vorinostat","volume":"1","author":"Duvic","year":"2007","journal-title":"Biol Targets Ther"},{"key":"10.1016\/j.bmcl.2018.06.029_b0015","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1756-8722-5-24","article-title":"Novel therapeutic agents for cutaneous T-cell lymphoma","volume":"5","author":"Jain","year":"2012","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bmcl.2018.06.029_b0020","first-page":"86","author":"Sloan","year":"2007"},{"issue":"9","key":"10.1016\/j.bmcl.2018.06.029_b0025","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1021\/acs.jmedchem.8b00067","article-title":"Rational drug design of topically administered caspase 1 inhibitors for the treatment of inflammatory acne","volume":"61","author":"Fournier","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2018.06.029_h0025","doi-asserted-by":"crossref","first-page":"225","DOI":"10.5582\/ddt.2014.01034","article-title":"HDAC1\/3 dual selective inhibitors \u2013 new therapeutic agents for the potential treatment of cancer","volume":"8","author":"Li","year":"2014","journal-title":"Drug Discov Ther"},{"key":"10.1016\/j.bmcl.2018.06.029_h0030","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmcl.2018.06.029_h0035","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2174\/1389557515666150521162237","article-title":"Histone deacetylase inhibitors: a review on class-I specific inhibition","volume":"15","author":"Behera","year":"2015","journal-title":"Mini-Rev Med Chem"},{"key":"10.1016\/j.bmcl.2018.06.029_b0035","doi-asserted-by":"crossref","first-page":"26926","DOI":"10.1074\/jbc.M113.490706","article-title":"Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability","volume":"288","author":"Lauffer","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2018.06.029_b0040","doi-asserted-by":"crossref","first-page":"14416","DOI":"10.1021\/ja805693p","article-title":"Chiral squaramide derivatives are excellent hydrogen bond donor catalysts","volume":"130","author":"Malerich","year":"2008","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmcl.2018.06.029_b0045","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/blood.V55.3.409.409","article-title":"Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas","volume":"55","author":"Gazdar","year":"1980","journal-title":"Blood"},{"key":"10.1016\/j.bmcl.2018.06.029_h0055","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.0022-202X.2005.23925.x","article-title":"Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action","author":"Zhang","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.bmcl.2018.06.029_h0060","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1002\/ijc.25218","article-title":"Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: defining molecular mechanisms of resistance","author":"Shao","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bmcl.2018.06.029_b0055","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ejca.2012.08.017","article-title":"Panobinostat activity in both bexarotene-exposed and -na\u00efve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial","volume":"49","author":"Duvic","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bmcl.2018.06.029_b0060","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1158\/1078-0432.CCR-13-0312","article-title":"A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors","volume":"19","author":"Venugopal","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmcl.2018.06.029_b0070","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1021\/jo100104g","article-title":"N, N\u2032-Diarylsquaramides: general, high-yielding synthesis and applications in colorimetric anion sensing","volume":"75","author":"Rostami","year":"2010","journal-title":"J Org Chem"},{"key":"10.1016\/j.bmcl.2018.06.029_b0075","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/j.tetlet.2016.04.003","article-title":"A facile and rapid preparation of hydroxamic acids by hydroxylaminolysis using DBU as base","volume":"57","author":"Beillard","year":"2016","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.bmcl.2018.06.029_h0085","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1039\/c2md00313a","article-title":"A medicinal chemistry perspective on melting point: matched molecular pair analysis of the effects of simple descriptors on the melting point of drug-like compounds","volume":"3","author":"Schultes","year":"2012","journal-title":"Med Chem Commun"},{"key":"10.1016\/j.bmcl.2018.06.029_h0090","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1021\/ci000338c","article-title":"Prediction of drug solubility by the general solubility equation (GSE)","volume":"41","author":"Ran","year":"2001","journal-title":"J Chem Inf Comput Sci"},{"key":"10.1016\/j.bmcl.2018.06.029_h0095","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1021\/jm900125m","article-title":"Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors","volume":"52","author":"Suzuki","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2018.06.029_h0100","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.pisc.2013.12.001","article-title":"Considerations for the design and reporting of enzyme assays in high-throughput screening applications","volume":"1","author":"Acker","year":"2014","journal-title":"Perspect Sci (Neth)"},{"key":"10.1016\/j.bmcl.2018.06.029_b0100","doi-asserted-by":"crossref","first-page":"6985","DOI":"10.1021\/jm4008642","article-title":"Evaluating the differences in cycloalkyl ether metabolism using the design parameter \u201clipophilic metabolism efficiency\u201d (LipMetE) and a matched molecular pairs analysis","volume":"56","author":"Stepan","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2018.06.029_b0105","doi-asserted-by":"crossref","first-page":"9063","DOI":"10.1021\/acs.jmedchem.5b00586","article-title":"New frontiers in druggability","volume":"58","author":"Kozakov","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2018.06.029_b0110","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1021\/jm0498497","article-title":"On the function of the 14 \u00c5 long internal cavity of histone deacetylase-like protein: implications for the design of histone deacetylase inhibitors","volume":"47","author":"Wang","year":"2004","journal-title":"J Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X18305183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X18305183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:27:28Z","timestamp":1760772448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X18305183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":23,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0960894X18305183"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2018.06.029","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Squaramides as novel class I and IIB histone deacetylase inhibitors for topical treatment of cutaneous t-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2018.06.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}